Exchange: NASDAQ·Updated 07:57 PM EST
IMDX logo

IMDX Insight Molecular Diagnostics Inc.

$1.97
$0.31
(18.68%)
Today
Closed $1.97
$0.00
(0.00%)
After Hours
Reported EarningsNov 16
Mkt Cap$64.53M
Vol1.2M

About IMDX

Insight Molecular Diagnostics, Inc. is a diagnostics technology company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The company was founded in September 2009 and is headquartered in Nashville, TN.
78

Extremely Bullish Sentiment

How do you feel about IMDX?

Jesse1011
$IMDX this just in…. As well as insiders buying $6,000,000 worth of shares on the open market with their own money!🔥 something’s cookin!
7
Jesse1011
$IMDX if insiders are investing $6,000,000 OF their money at the market price I’ll toss in 17k Thanks to who cross posted this💪
4
z06forum
$IMDX cup and Handle forming on the 5 day. Watch for breakout above 3.26 then Blue sky to 3.70...
4
RUNNINWILD
$IMDX the short term is going to be interesting to see if broadwood or any of the directors/ management buys any stock at these prices. If they don’t would take that as a very bad sign
3
matthew122
$IMDX wow getting clean funding like straight common in this environment is amazing. Great to see IMDX funded and ready to go!
3
Invest123455
$IMDX Given Neal Bradsher’s 25-year activist playbook at Broadwood Partners (especially at STAAR Surgical, Lineage Cell Therapeutics, and Bio-Rad), he does not tolerate repeated execution slips without demanding structural changes. CEO was very weak today, perfect time to fire him.
3
Double_it_Helix
$IMDX Management reported growing interest from major US reference laboratories in adopting in-house donor-derived cell-free DNA testing.<
3
Bogwood
$IMDX Man I really want to believe the 10-Q is parlayed with approval, but it's such a coin flip and not an assymetric bet imo. On one hand it doesn't make sense to poach Donnie if the authorization is doomed, which gives further credit to why a raise hasn't happened yet. But it's just as likely that the SIR delays us into '27, which is obviously why an approval announcement hasn't been made yet. So like before, I have dry powder on the sidelines, but only a measly 3% weight heading into earnings.
3
Bogwood
$IMDX To not hear that the package was resubmitted is the big downer this quarter. It's apparent this team was given a novice FDA partner throughout its prep phrase. So to me, it's not fair to blame management based on what they were guided to submit. It just doesn't add up when considering Tampa General's presentation from April- over 140 samples with over 99% agreeance to Prospera, with PPV at 80%. I get that the FDA wants to be safe than sorry, but tripling the already stat-significant samples while sending to two more pathology "reviewers" will just confirm what we already know... Approval no sooner than mid-March, so no need to buy anytime soon before the big announcement.
1
DilutionScan
$IMDX priced an underwritten offering at $1.75 a share, per the 424B5 accepted 6:30 AM ET. Bank named in the prospectus: Lake Street Capital Markets.
1
Wisenheimer
$IMDX this was back in august - I believe we will now see the need for a reverse split and ultimately need to raise 40m plus.
StocktwitsEarnings
$IMDX Q3 '26 Earnings Results & Recap Insight Molecular Diagnostics continues to target outgoing free cash flow of approximately $8M in Q4 2026; Q3 2026 free cash flow was approximately $7.3M, versus prior expectation of $8M.
z06forum
$IMDX IMDX has announced the commencement of the offering, but it has not announced the final terms. Lake Street will work with institutional investors to determine: How much capital investors are willing to commit. What price they are willing to pay. How many shares or pre-funded warrants they will purchase. This is effectively a book-building process. The final price and size are generally established when the underwriting agreement is finalized. Why is this being done now? The company specifically says the money will go toward: Working capital. General corporate purposes. Research and development in transplantation. That last point is important. Management is specifically identifying transplantation as a priority for the proceeds.

Advertisement|Remove ads.